#aptamer

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company. The expanded partnership will focus on developing Optimer® binders against three therapeutic targets to support drug validation and potential clinical trial applications. New multi-target development…

DNA Aptamer Breakthrough: Targeting Colorectal Cancer Stem Cells 🧬🎯

Unlock the future of cancer treatment with our latest video on the revolutionary "DNA Aptamer Breakthrough: Targeting Colorectal Cancer Stem Cells." 🌟 Dive into how scientists are using engineered DNA strands to specifically target colorectal cancer stem cells, offering hope for early detection and personalized therapies. This innovative approach could reshape cancer diagnosis and significantly improve treatment outcomes while minimizing side effects.

Nomination & Contact Details

Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD).

  It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America.  This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies. This has led to rapid developments in the domain which can be attributed to various factors, such as number in the number of clinical trials, increased awareness about advantages offered by aptamers as compared to antibodies, rise in the investment in the pharmaceutical research and development, along with rise in prevalence of chronic and rare diseases have contributed to the increase in the demand for aptamers-based therapeutics and diagnostic solutions.  Aptamers are developed through the SELEX process and over the years these have become primary tools for aptamer synthesis.  To ensure the development of more effective aptamer-based therapies candidates, several players have developed novel aptamer technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment. 

 To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market/request-sample.html

 Over the past three decades, since the invention of SELEX by Larry Gold and Jack William in the 1990, the technology has seen several modifications to streamline and standardized aptamer-isolation process. These modifications substantially enhance efficiency / optimization to yield best possible aptamer or reduce the duration of the process. Other noteworthy developments in modifications of aptamers, include the addition of functional units of non-nucleic origin and nucleotide modifications, which further improves aptamer performance.

 Steps involved in the SELEX process:

§  Library Generation: Oligonucleotide library is created containing single-stranded nucleic acids having random sequences flanked by binding sites.

§  Binding and Separation: Target molecule is incubated along with the oligonucleotide library allowing for nucleic acids to bind to them resulting in the formation of aptamers. The remaining unbound nucleic acids are filtered out of the solution and through the process of elution the bound nucleic acid is separated from the target.

§  Amplification: The nucleic acids separated through the process of elution are then used to create a new library using the Polymerase Chain Reaction (PCR), this provides a new library that can be utilized for new round of SELEX thus, improving the quality of aptamers synthesized

Advantages of Aptamers

For many years, researchers have been raising and modifying antibodies to detect specific circulating proteins and develop targeted therapeutic agents. While antibodies are highly effective for a wide range of applications, there are unique aptamer advantages that can overcome some difficult scientific challenges.

§  Targets small molecules: Flexibility of aptamers offer wider applications as they can be developed against molecules as small as 60 Daltons this means aptamers can target molecules that are ten times smaller than antibody targets. Currently, aptamers for small molecule drugs, peptides, dyes and viral particles have been developed successfully.

§  Pursue toxic and non-immunogenic targets: Aptamer development process does not involve animals or living cells thus, making it possible to select aptamers for toxic compounds such as zootoxins and pathogenic bacteria. Additionally, aptamers do not require immune response and binding of tertiary aptamer structures to target molecules.

§  Penetrate tissues and cells: Due to their small size (30-80 nucleotides), they have enhanced ability to penetrate tissues thus, allowing them to reach specific targets efficiently. Some aptamers are able to enter cells without external assistance.

 For additional details, please visit:- https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market.html

 You may also be interested in the following titles:

1.       Targeted protein degradation market, 2022-2035

2.       Gene Editing beyond CRISPR Market, 2022-2035

3.       Cell and Gene Therapy Bioassay Services Market, 2021-2030

 Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

After an aptamer is selected we can suggest specific modifications to improve its properties based on your requirements e.g cell delivery, nuclease resistance, duplex stability etc. Moreover, biotinylation, fluorophores, backbone modifications and other functionalizations are all available.

Aptamers – What are they and their usage-

Aptamers can be defined as short strands of nucleic acids or peptide molecules that are capable of forming secondary and tertiary structures. These molecules are capable of binding specifically to the cellular targets and are created by selecting randomly from complex libraries of synthetic nucleic acids. These receptor modules can be modified to enhance the stability and availability of biological environments. Aptamers have potential applications in the field of research, clinical, industrial and medical areas. Aptamers molecules have been in use ever since in the 1990s for their clinical relevance.

Aptamers Market Global Industry Analysis – An Insider Story

The global aptamers market is still in its nascent stage as aptamers are not able to establish their strong presence in the market even though; they have distinct advantages over protein therapeutics. However, the emergence of aptamers molecules in various diagnostic and therapeutic applications holds immense growth prospects in distant future. According to the report, the aptamers market worth was USD 128.03 million in 2016 with an impressive CAGR of 18% global aptamers market growth is poised to reach USD 293 million by the end of 2021.

The global aptamers market size is witnessing a huge growth owing to vast amounts being spent on higher research and development activities and investments in pharmaceutical and biotechnological companies. Aptamers market got a boost with the launch of Macugen – the first aptamers drug and the first diagnostic test for testing mycotoxins in grains has recognized the potential of aptamers in diagnostic and therapeutic applications.

Download free sample report: http://www.marketdataforecast.com/market-reports/global-aptamers-market-1134/request-sample

Aptamers Market – Drivers and Restraints

The extensive use of aptamers in the drug discovery and disease treatment will help in bolstering the aptamers market. The RNA aptamers have proved to be having high therapeutic and diagnostic value and approved by FDA (Food and Drug Administration) of United States of America. The first aptamer based therapeutic for the treatment of age related macular degeneration was approved by FDA way back in 2004 with many other aptamer molecules are being evaluated in clinical trials.

Ethical issues, stringent regulations restrain the market and slow demand owing to regulatory hurdles is hampering the growth of this market. However, the technological advances in the field of targeted therapies, nanotechnology and medical imaging would facilitate the sustainable growth of the global aptamers market.

Market Segmentation of Aptamers Market – A brief overview

The global aptamers market is broadly categorized or segmented into Type, Application, and End Users and each of these segments are further subdivided that is shown in a tabular format for the ease of understanding the aptamers market herein below-

TypeApplicationEnd UsersNucleic Acid Aptamers – (DNA-Based Aptamers, RNA-Based Aptamers, XNA– Based Aptamers)Therapeutics DevelopmentPharmaceutical CompaniesPeptide AptamersDiagnosticsBio-Pharmaceutical CompaniesResearch & DevelopmentAcademic and Research CentersClinical Trials

Figure: 1 – Market Segmentation of Global Aptamers Market

Based on the type of aptamers market, DNA Based Aptamers occupies the highest share in the market and XNA-Based Aptamers accounts for the highest CAGR during 2016. The nucleic acid aptamers are gaining enough ground as a substitute for protein based targeting approaches. This market for nucleic acid aptamers is expanding due to the rising number of leading companies or players who are collaborating with various organizations and research institutions to develop customized nucleic acid aptamers. In the application segment/category – the therapeutics is expected to be enjoying a dominant share in the aptamers market by registering a strong growth of CAGR of 21%.

Customize report: http://www.marketdataforecast.com/market-reports/global-aptamers-market-1134/customize-report

Geographically, North America dominates the global market with the highest share followed by Europe and Asia-Pacific region. Asia-Pacific region is emerging as a playing ground for tapping increased opportunities in diagnostic and development of pharmaceuticals that remains untapped in the aptamers market. The major key players or companies in aptamers market include-

• Aptamer Solutions Ltd • Aptus Biotech S.L. • Base Pair Biotechnologies Inc • NeoVentures Biotechnology Inc • SomaLogic Inc • Vivonics Inc

Aptamers Market Analysis Research Report 2017 is a premium research explores Global Aptamers Market Size, Share, Statistics, Growth, Potential, Opportunity and Company analysis to 2020. Aptamers Market particularly focusing on Aptamers Demand, Market Drivers, Challenges, Major trends, and value chain Analysis. Global Aptamers Market set to hit $244.93 million by 2020 at a CAGR of 17.89% by 2020.

Inquire for this complete Aptamers Market Report of 125 pages including tables and figures with companies SWOT analysis at:  http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=258340

The aptamer type segments included in this report are DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. Based on applications, the report is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications will hold the largest share of the aptamers market in 2015. The therapeutics development application is expected to be one of the fastest-growing applications between 2015 and 2020.

Report displays Aptamers by – Type (DNA, RNA, and XNA), Application (Diagnostics, Therapeutics, R&D), Technology (SELEX, Other Technologies) & by End Users (Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO).

The geographic segments included in this report are the Americas, Europe, Asia, and the Rest of the World (RoW). The geographic analysis reveals that the Americas are expected to account for the largest share in the global aptamers market in 2015. Europe is expected to register the fastest growth.

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Furthermore, the patent expiration of systematic evolution of ligands by exponential enrichment technology (SELEX), technological advancements, and the low cost and high efficiency of aptamers in binding to large molecules as compared to antibodies will aid the growth of the global aptamers market.

To know about the assumptions considered for the study visit at: http://www.reportsnreports.com/contacts/requestsample.aspx?name=258340

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global aptamers market and its sub segments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antibody alternatives in specific aptamer 3-D scaffold binding

Antibody alternatives in specific aptamer 3-D scaffold binding

Larry H. Bernstein, MD, FCAP, Curator

LPBI

    New Proteomics Tools to Open Up Drug Discovery

Dr. Paul Ko Ferrigno, Chief Scientific Officer, and Dr. Jane McLeod, of Avacta Life Sciences

http://www.dddmag.com/articles/2016/01/new-proteomics-tools-open-drug-discovery

  http://www.dddmag.com/sites/dddmag.com/files/AvactaAffimer%20still…